Los Angeles Capital Management LLC Mirum Pharmaceuticals, Inc. Transaction History

Los Angeles Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 05, 2024	BUY	$24.92 - $30.02 $101,399 - $122,151	4,069 Added 10.77%	41,836 $1.05 Million
Q4 2023 Feb 06, 2024	SELL	$27.14 - $34.93 $126,933 - $163,367	-4,677 Reduced 11.02%	37,767 $1.11 Million
Q3 2023 Nov 06, 2023	BUY	$24.63 - $32.85 $12,167 - $16,227	494 Added 1.18%	42,444 $1.34 Million
Q2 2023 Aug 03, 2023	BUY	$23.51 - $30.09 $986,244 - $1.26 Million	41,950 New	41,950 $1.09 Million
Q3 2022 Nov 02, 2022	SELL	$19.98 - $29.44 $241,498 - $355,841	-12,087 Reduced 40.81%	17,533 $368,000
Q2 2022 Aug 05, 2022	BUY	$18.42 - $27.5 $545,600 - $814,550	29,620 New	29,620 $576,000
Q1 2022 May 06, 2022	SELL	$15.5 - $23.93 $334,412 - $516,289	-21,575 Closed	0 $0
Q4 2021 Feb 03, 2022	SELL	$13.05 - $19.35 $10,896 - $16,157	-835 Reduced 3.73%	21,575 $344,000
Q3 2021 Nov 08, 2021	BUY	$13.95 - $20.18 $20,506 - $29,664	1,470 Added 7.02%	22,410 $446,000
Q2 2021 Aug 05, 2021	BUY	$15.84 - $20.6 $26,389 - $34,319	1,666 Added 8.64%	20,940 $362,000
Q1 2021 May 05, 2021	BUY	$16.29 - $21.92 $313,973 - $422,486	19,274 New	19,274 $382,000

190

54M

177K

167K

Ticker MIRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,751,700
Market Cap $1.64B
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.